ANDA 206681, held by Piramal Critical. Oxacillin Sodium.
As of Nov 15, 2026, ANDA 206681 (Oxacillin Sodium), held by Piramal Critical, was first approved by FDA on Sep 11, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2017 | Original application | Approved | None posted |
| Oxacillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
| Oxacillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Oxacillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
